Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Novavax Q3 2026 Results: Net Loss of $31.4M, Loss Narrows

Novavax reported total revenue of $68.3 million for the third quarter of 2026, a slight decrease from $70.4 million in the prior year, while net loss narrowed significantly to $31.4 million compared to $202.4 million. For the nine-month period, the company experienced a net loss of $94.3 million, a sharp reversal from the $422.8 million net income recorded in the same period of 2025, primarily due to a substantial drop in product sales and licensing revenue.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue68.370.4
Profit before tax-29.7-203.0
Net income-31.4-202.4
EPS (diluted, $ a share)$-0.19$-1.25

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-3.0%
Operating margin-45.8%
Source

10-Q filed with the SEC, NASDAQ: NVAX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Novavax Inc: key numbers

Share price
$8.06Close, Nov 16
Market cap
$1.33B
Shares outstanding
165.01MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Novavax Inc

All →
8:09 AM ET 8-K
Financial Results

Novavax Financial Results

Novavax reported Q3 2026 total revenue of $68 million and raised its full-year 2026 revenue guidance to $400 million at the mid-point. The company also earned a $125 million milestone payment from partner Sanofi following the initiation of a Phase 3 combination vaccine trial in Europe.

“This quarter, we continued to execute across all three pillars of our strategy. Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment. Our focused R&D efforts are building a growing body of data on what our technology can do in infectious disease, advancing our C. difficile candidate towards the clinic and exploring oncology as a potential new area of application. And we have been doing this while continuing to reduce expenses and operate with financial discipline. Over time, we believe this strategy can build a robust and profitable Novavax, with multiple partners and products, diversified revenue streams and a meaningful impact on global health.”

John C. Jacobs, President and Chief Executive Officer, Novavax
4:30 PM ET 8-K
Business Update

Novavax Business Update

Novavax earned a $125 million milestone payment from Sanofi following the dosing of the fifth patient in a Phase 3 influenza-COVID-19 combination vaccine trial in the European Union. The trial utilizes Novavax's Nuvaxovid COVID-19 component in combination with Sanofi's high-dose flu vaccine. Novavax expects to receive the payment by the first quarter of 2027 and remains eligible for further clinical and regulatory milestones.

Counterparty
Sanofi Pasteur Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.